Squamous cell carcinoma of head and neck
RecruitingStudy of Carboplatin, Paclitaxel, and Cetuximab for Patients with Recurrent or Metastatic Head and Neck Cancer After Pembrolizumab Treatment Failure
Study of Carboplatin, Paclitaxel, and Cetuximab for Patients with Recurrent or Metastatic Head and Neck Cancer After Pembrolizumab Treatment Failure
- Disease:Squamous cell carcinoma of head and neck
- Substances:CarboplatinCetuximab+1
France- Participants:18–64 years · 65+ years
- Substances:Carboplatin
- Sponsor:Centre Regional Lutte Contre Le Cancer




